All photos on this site are actor portrayals.
MYOBLOC has demonstrated efficacy in treating CD in 11 clinical studies.1
MECHANISM OF ACTION2,3
Blocks the release of acetylcholine (ACh) to inhibit muscle contraction.
- MYOBLOC has been demonstrated to cleave synaptic vesicle-associated membrane protein (VAMP)*
- This blocking action allows the injected muscle to assume a more normal tone

1. BINDING
Neurospecific binding of the toxin on the presynaptic nerve surface

2. INTERNALIZATION
of the toxin by receptor-mediated endocytosis

3. TRANSLOCATION
Subsequent translocation of the toxin light chain into the cytosol

4. CLEAVAGE
Modificaion of an intracellular target substrate that governs the docking and fusion of ACh-containing vesicle
*VAMP is a component of the protein complex responsible for the docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.
EFFICACY IN CERVICAL DYSTONIA
As the first botulinum toxin injection approved by the FDA for CD, MYOBLOC is a well-studied treatment with demonstrated efficacy in adults2
Click each to see specific data
- Toxin A-Responsive and Toxin A-Resistant Patients
- Toxin A-Responsive Patients
- Toxin A-Resistant Patients
- Toxin-Naive Patients: MYOBLOC vs. BOTOX
- Long-Term, Open-Label Study
For definitions of rating scales and measurements click here
Study 44
A randomized, double-blind, multicenter, placebo-controlled, 16-week trial
- 122 patients enrolled
- 4 dose arms: 2,500 Units (n=31), 5,000 Units (n=31), or 10,000 Units (n=30) vs. placebo (n=30)
- Objectives: Determine the safety and efficacy of MYOBLOC in both A-responsive and A-resistant patients with CD
TOXIN A-RESPONSIVE AND TOXIN A-RESISTANT PATIENTS2,4
Significant pain relief as early as 2 weeks.
Study 15
A randomized, double-blind, multicenter, placebo-controlled, 16-week trial
- 109 patients enrolled
- 3 dose arms: 5,000 Units (n=36) or 10,000 Units (n=37) vs. placebo (n=36)
- Objectives: Determine the safety and efficacy of MYOBLOC in patients with CD who were responsive to Toxin Type A
TOXIN A-RESPONSIVE PATIENTS2,5
Fast and effective pain relief
Study 26
A randomized, double-blind, multicenter, placebo-controlled, 16-week trial
- 77 patients enrolled
- 2 dose arms: 10,000 Units (n=39) vs. placebo (n=38)
- Objectives: Determine the safety and efficacy of MYOBLOC in patients with CD who were resistant to Toxin Type A
TOXIN A-RESISTANT PATIENTS2,6
Significant pain relief in as early as 2 weeks
Although there was a MYOBLOC-associated decrease in pain, many patients remained who experienced an increase in dystonia-related neck pain irrespective of treatment group
Study 4027
A randomized, double-blind, multicenter, noninferiority trial
- 93 patients new to treatment with botulinum toxins were analyzed7
- 2 dose arms: BOTOX 150 Units (n=47) or MYOBLOC 10,000 Units (n=46)
- Objectives: Compare the efficacy, safety, and duration of effect of BOTOX with MYOBLOC in toxin-naive patients with CD
TOXIN-NAIVE PATIENTS
Head-to-head study: MYOBLOC vs. BOTOX®
Noninferiority of MYOBLOC vs. BOTOX was established7
Long-Term, Open-Label Study1,8
427 patients (mean age, 55.1 years) enrolled in the multicenter study, which represented the largest prospective report of long-term, open-label MYOBLOC treatment in CD. On the first injection, patients were administered 5,000 Units (toxin-naive patients who previously received placebo), 10,000 Units, or the highest MYOBLOC dose previously received. Re-injection occurred when the patient returned to approximate CD baseline status at least 3 months from their last injection. TWSTRS scales were performed at baseline and 4 weeks post-treatment.
Persistent pain relief effect at Week 4 following each injection in this large, prospective, multicenter, open-label extension trial
Patients demonstrated improvements of baseline TWSTRS scores through 12 treatment sessions
MYOBLOC provided lasting, effective relief of abnormal head posture and neck pain in CD for up to 16 weeks2
Proven to relieve the severity of abnormal head position and neck pain associated with CD in adults.

PAIN RELIEF
as early as

SIGNIFICANT
improvement in head posture by

DURATION
of action

READY TO USE
and requires no mixing2
SAFETY & TOLERABILITY2
Safety profile comparable to BOTOX*,7
*Categories of interest have been defined as “dry mouth,” “dysphagia,” and “injection-site pain” because they represent frequent adverse events that have been associated with both botulinum toxin serotypes; treatment-related incidence is the same as overall incidence for these events. No other treatment-related adverse events occurred in >10% in either BOTOX or MYOBLOC in the intent-to-treat population.
†Fisher’s exact test (BOTOX vs. MYOBLOC).
RATING SCALES AND MEASUREMENTS EXPLAINED:
TWSTRS: A VALIDATED SCALE FOR ASSESSING CERVICAL DYSTONIA2,9
TWSTRS is an assessment scale used to measure the impact of cervical dystonia on patients. It is frequently used in clinical trials for cervical dystonia, including trials for MYOBLOC.
It is comprised of 3 subscales: Severity, Disability, and Pain, each of which is scored independently. The total of these 3 comprises the TWSTRS total score, which is scored from 0-87 (best to worst).
Abbreviation: TWSTRS, Toronto Western Spasmatic Torticollis Rating Scale.
VISUAL ANALOG SCALE (VAS)2,9
The VAS is a subjective scale used for assessing a variable such as patient-reported pain. It is a 100-mm line, usually horizontal, anchored on both ends with descriptors (0=Worst ever pain, 100=No pain). A patient marks the point that he/she feels represents the variable being measured (eg, pain). The score, from 0 to 100, is determined by measuring from the end of the line to the patient's mark. A 100-point VAS was used in pivotal clinical trials for MYOBLOC.